Lyka Labs Secures Indian Patent for Pregabalin Gel for Neuropathic Pain

Lyka Labs Limited has revealed that it has received an Indian patent for its unique product, Pregabalin Gel 8 percent, with patent protection lasting until 2043.

In October 2024, the Central Drugs Standard Control Organization (CDSCO) regulatoryly approved the production and marketing of Pregabalin Gel 8%, a topical formulation intended to effectively control diabetic neuropathic pain, in India. Nerve damage resulting in pain, numbness, and other feelings, usually in the feet and legs but often in other locations, is known as diabetic neuropathic pain, and it is a common consequence of diabetes.

Under a P2P (Product-to-Product) license from Lyka Labs, the product was formally introduced by Torrent Pharmaceuticals, Zuventus Healthcare, and Intas Pharmaceuticals in December 2024. By providing localized pregabalin administration at the pain site, this gel formulation may reduce systemic exposure and accompanying side effects that are frequently linked to oral formulations.

With clinical studies demonstrating Pregabalin Gel 8%'s effectiveness, safety, and patient convenience, Lyka Labs has given millions of people with long-term diabetic neuropathic problems an option.

Lyka is a pharmaceutical firm that specializes in topical and sterile preparations. In its focus areas of topical preparations and lyophilized injectables, Lyka is presently developing a variety of new formulations and drug delivery systems from its R&D Center in Mumbai.